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Ovarian cancer is still the deadliest of all gynecologic malignancies in women worldwide.
This is attributed to two main features of these tumors, namely, (i) a diagnosis at an
advanced tumor stage, and, (ii) the rapid onset of resistance to standard chemotherapy
after an initial successful therapy with platin- and taxol-derivatives.Therefore, novel targets
for an early diagnosis and better treatment options for these tumors are urgently needed.
Epidemiological data show that induction and biology of ovarian cancer is related to life-time
estrogen exposure. Also experimental data reveal that ovarian cancer cells share a number
of estrogen regulated pathways with other hormone-dependent cancers, e.g., breast and
endometrial cancer. However, ovarian cancer is a heterogeneous disease and the subtypes
are quite different with respect to mutations, origins, behaviors, markers, and prognosis
and respond differently to standard chemotherapy. Therefore, a characterization of ovar-
ian cancer subtypes may lead to better treatment options for the various subtypes and in
particular for the most frequently observed high-grade serous ovarian carcinoma. For this
intention, further studies on estrogen-related pathways and estrogen formation in ovarian
cancer cells are warranted. The review gives an overview on ovarian cancer subtypes and
explains the role of estrogen in ovarian cancer. Furthermore, enzymes active to synthe-
size and metabolize estrogens are described and strategies to target these pathways are
discussed.
Keywords: ovarian cancer, estrogen synthesis, estrogen sulfotransferase, estrogen sulfatase, estrogen receptor
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GENERAL INTRODUCTION
Currently, ovarian cancer is the fifth most common cancer in
women in industrialized countries. It is mainly a disease of post-
menopausal women, because more than 80% of all cases are being
diagnosed in women older than 50 years. Although a falling rate
of new ovarian cancer cases of 1.1% each year and an increase
in the relative 5-year survival time from 33.6% in 1975 to 45.2%
in 2010 was observed in industrialized countries, ovarian cancer
is still the deadliest of all gynecologic malignancies worldwide.
The alarming data are greatly attributed to the generally late diag-
nosis of the disease. More than 80% of all newly detected cases
are advanced epithelial ovarian cancers (EOC) with peritoneal
metastases and/or metastases in distant organs [Féderation Inter-
nationale de Gynécologie et d’Obstétrique (FIGO) stage III–IV].
Abbreviations: CCC, clear cell carcinoma; CYP, cytochrome P450 enzyme; DHEA(-
S), dehydroepiandrosterone(-sulfate); EC, endometrial ovarian carcinoma; EOC,
epithelial ovarian cancer; ER-α, estrogen receptor-α; ER-β, estrogen receptor-β; ERR-
α, estrogen-related receptor-α; E1, estrone; E1-S, estrone-sulfate; E2, 17ß-estradiol;
E3, estriol; FIGO, Féderation Internationale de Gynécologie et d’Obstétrique; FSH,
follicle stimulating hormone; GPER, G-protein-coupled estrogen receptor; HGSC,
high-grade serous ovarian cancer; HRT, hormone replacement therapy; LGSC, low-
grade serous ovarian cancer; LH, luteinizing hormone; MC, mucinous carcinomas;
OATP, organic anion transporting polypeptide; OCP, oral conceptive pill; OSE,
ovarian surface epithelium; PGR, progesterone receptor; SERM, selective estrogen
receptor modulators; STIC, serous tubal intraepithelial carcinoma; STS, steroid sul-
fatase; SULT, sulfotransferase; SULT1E1, estrogen sulfotransferase; 4-OH-E1/E2, 4-
hydroxy E2/E1; 5-Diol-S, 5α-androstenediol sulfate; 17β-HSD, 17β-hydroxysteroid
dehydrogenases.
The FIGO staging system was established by the FIGO and is most
commonly used in EOC diagnosis (1). Effective preventative mea-
sures and reliable screening tools for an early detection are not yet
available. Although the majority of women experience a variety
of non-specific symptoms in the year before diagnosis, the disease
is not commonly recognized until the tumor reaches an advanced
stage. Another problem is the early development of resistance to
the standard chemotherapy regimens with cisplatin/oxaliplatin in
combination with paclitaxel. This leads to an early relapse and
tumor progression. Considering these problems, it is clear that
reliable diagnostic tools for an early detection of these cancers and
more treatment options are urgently needed (2–4).
Epidemiological data show that induction and biology of ovar-
ian cancer is related to estrogen exposure and metabolism. Experi-
mental data demonstrated that ovarian cancer cells share a number
of estrogen regulated pathways with other hormone-dependent
cancers such as breast and endometrial cancer. Such pathways were
studied in more details already in these tumors (5–7).
This review gives an overview on ovarian cancer heterogene-
ity and estrogen-related mechanisms in ovarian cancer biology.
Thereby, data on enzymes active to synthesize and inactivate estro-
gens as well as on estrogen receptors (ER) are shown and strategies
to target these pathways are discussed.
OVARIAN CANCER AS A HETEROGENEOUS DISEASE
CLASSIFICATION
More and more, the classification of the heterogeneous group
of ovarian carcinomas is coming into focus of research and
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ovarian cancer subtypes with different behaviors, mutations, ori-
gins, markers, and prognosis are characterized at a molecular level
for their molecular signature. Since subtypes of ovarian cancer
respond differently to the common therapies, a characterization
of the tumor type is very important for a successful treatment (8).
Epithelial ovarian cancer is the most frequent tumor in the
ovary as up to 98% of all cases are classified as EOCs. To this
group belongs the most common and also the most deadly ovar-
ian cancer, the high-grade serous ovarian cancer (HGSC), showing
a frequency of 70%. It is followed by endometrial ovarian carci-
nomas (EC) and clear cell carcinomas (CCC) with frequencies of
10% for each entity, low-grade serous ovarian carcinomas (LGSC)
with 5%, and mucinous carcinomas (MC) with 3% frequency (9).
Other tumors, e.g., stromal cord tumors, teratomas, etc., are only
rarely observed (10).
A summary of the predicted origins of different ovarian cancer
subtypes and the mutations frequently found in these tumor types
is given in Table 1.
Several immunohistochemical and genetic analyses have been
done to detect differences and identify features of ovarian cancer
subtypes. Köbel et al. (13) did biomarker analyses and came to
the conclusion that some biomarkers, e.g., Ki-67 as a cell prolif-
eration marker, Williams tumor protein 1 and also CA125 show
significant differences in expression rates between the subtypes.
Therefore, they can be used as subtype specific biomarkers.
The serous subtypes are classified as low-grade (LGSC) and
high-grade (HGSC). LGSC and HGSC represent two distinct
tumor types with a different underlying pathogenesis rather than
low-grade and high-grade variants of the same neoplasm. Both
are usually at advanced stage at the time of diagnosis (FIGO stage
III or IV). BRAF (v-raf murine sarcoma viral oncogene homolog B)
and KRAS (Kirsten rat sarcoma viral oncogene homolog ) mutations
are important molecular events in LGSC, while HGSC as the most
common subtype of ovarian cancer is almost always associated
with p53 mutations. HGSC arises from the epithelium of the distal
fallopian tube and not from the ovarian epithelial cells (9). In con-
trast to the serous tumors,EC and CCC are typically present as low-
stage neoplasms and usually arise from endometriosis. Primary
ovarian MCs are almost always unilateral and FIGO stage I tumors.
This group consists mainly of so-called intestinal or enteric type
MCs. Generally, MCs arise in a step-wise manner from a pre-
existing mucinous cystadenoma or mucinous borderline tumor.
Another system classifies different ovarian cancer subtypes
(mentioned above) into type I and type II tumors. Type I tumors
(LGSC, low-grade EC, CCC, and MC) are generally slow grow-
ing and genetically more stable than type II tumors. A step-wise
progression from a benign precursor lesion (endometriosis in the
case of endometrioid tumors) to borderline tumors and next to
the invasive tumors is characterized by genetic aberrations target-
ing specific cell signaling pathways, e.g., KRAS or BRAF mutations.
Type II tumors (HGSC, high-grade EC, and undifferentiated carci-
nomas) are clinically aggressive and exhibit high genetic instability
with frequent p53 mutations (14).
SEROUS OVARIAN CARCINOMA SUBTYPES
High-grade serous carcinoma
High-grade serous ovarian carcinoma is a highly aggressive tumor,
which is usually detected in an advanced stage. After initially
responding to standard platin- and taxane-based chemotherapy,
the majority of patients will experience recurrence and develop
resistance to therapeutic drugs within 24 months (8, 15). Early
peritoneal metastasis is also common (16). The pathological mor-
phology of HGSC is heterogeneous showing a papillary, glandular,
or solid architecture. The tumor cells form large multi-layered
epithelial areas, which are surrounded by tumor stroma. Mononu-
clear giant cells with large nuclei are commonly found in these
tumors (13).
In contrast to LGSCs, HGSCs have a very high mitotic rate and
usually carry mutations in the p53 gene. HGSCs are characterized
by a high chromosomal instability. Loss of function mutations in
the breast cancer type susceptibility genes 1 and 2 (BRCA1/2) are also
associated with HGSC. Somatic mutations in, e.g., neurofibromin
(NF1) and cyclin-dependent kinase (CDK)12 genes are common
(9, 12, 16).
While previous models predict that HGSC develops from inclu-
sion cysts of the ovarian epithelium, it is now agreed that HGSC
arises from the serous tubal intraepithelial carcinomas (STICs).
The latter develop from cells on the junction of the fallopian tube
epithelium with the mesothelium of the tubal serosa. Cells there
undergo malignant transformation and metastasize to the nearby
ovary and later into the surrounding pelvic peritoneum.
Serous tubal intraepithelial carcinomas have mostly the same
p53 mutations, express the same oncogenes and also have simi-
lar phenotypic characteristics as HGSCs (15). STICs are found in
Table 1 | Origins and significant mutations of the EOC subtypes.
EOC subtypes Predicted origin Frequent Mutations
HGSC (high-grade serous carcinoma) STICs (serous tubal intraepithelial carcinoma) BRCA1/2, p53, NF1, CDK12, chromosomal instability
LGSC (low-grade serous carcinoma) Borderline tumors of the ovary BRAF, KRAS
EC (endometrial carcinoma) Atypical endometriosis, uterus CTNNB1, PTEN, ARID1A
MC (mucinous carcinoma) KRAS, HER2
CCC (clear cell carcinoma) Atypical endometriosis, uterus ARID1A
BRCA1/2, breast cancer 1/2, early onset; NF1, neurofibromin 1; BRAF, BRaf proto-oncogene, serine/threonine kinase; KRAS, Kirsten rat sarcoma viral oncogene
homolog; CTNNB1, catenin (cadherin-associated protein), beta 1; PTEN, phosphatase and tensin homolog; ARID1A, AT rich interactive domain 1A, HER2, tyrosine
kinase-type cell surface receptor HER2.
Singer et al. (11), Shih Ie and Kurman (12), Köbel et al. (13), and Gilks and Prat (9).
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67% of all HGSC cases (17). They are also associated with BRCA1/2
mutations (18).
High-grade serous ovarian cancer tumors in patients with
mutated BRCA1/2 have a more aggressive behavior and high-grade
histology, but they are frequently responsive to chemotherapy. In
many cases, their high sensitivity to the platinum-based regimens,
may lead to a slightly improved 5-year survival (19).
Low-grade serous ovarian carcinoma
Low-grade serous ovarian cancer is rather rare with <5% of all
EOCs. LGSCs are thought to develop stepwise from benign serous
cystadenomas via the formation of serous borderline tumors to
the final carcinoma. However, LGSCs rarely transform to HGSC
tumors (9, 20). If LGSCs are detected at an earlier stage, the
prognosis after treatment is favorable. Even for patients with
advanced stage tumors, the 5-year survival is longer than that for
HGSC patients, although LGSCs are quite resistant to conven-
tional chemotherapy. Similar to HGSC, this subtype often spreads
intraperitoneally (21). In the histological picture, micropapillary
structures and psammoma bodies (which are calcium incorpora-
tions that are formed from necrotic tumor cells) are frequently
seen. LGSC cells have rather uniform nuclei and a much lower
mitotic rate than HGSC tumor cells. Genetically, there is less chro-
mosomal instability in LGSC than in HGSC. However, the presence
of BRAF and KRAS mutations, as well as mutations in other genes
(Table 1) is common (11, 16).
OVARIAN CANCER AS A HORMONE-DEPENDENT CANCER
EPIDEMIOLOGICAL DATA
There is strong epidemiological evidence that etiology, pathogen-
esis, and progression of ovarian cancers are greatly dependent
on the activity of estrogens. Furthermore, the balance between
estrogen and progesterone is critical for the formation of ovarian
cancers (22).
Statistical analyses show that the incidence of ovarian cancer is
much higher in industrial countries than in developing countries.
The birth rates in industrial countries are low compared to devel-
oping countries (23). There is strong evidence that reproductive
factors including multiple pregnancies, breastfeeding, and use of
oral conceptive pill (OCP) protect against ovarian cancer. With
each pregnancy, the risk of developing ovarian cancer decreases by
10–16% and a pregnancy at the age of 35 years is twice as protective
as at the age of 25 years (24, 25). Also, a significant protective effect
is seen in women that do breastfeeding for more than 18 months
(26, 27). Similarly, application of OCP for more than 3 years causes
a 30–50% reduced risk of developing ovarian cancer (28).
In contrast to these protective factors, women with an early
first period and a late menopause as well as women that receive
drugs for the treatment of infertility (gonadotropin releasing-
hormone antagonists or clomiphene) have an increased risk of
developing ovarian cancers. The latter is thought to be caused
by high concentrations of estrogen after stimulation of the sex-
steroid hormone synthesis in the ovary (29). Also, application of
hormone replacement therapy (HRT) was found to be a risk fac-
tor for ovarian cancer. An approximately 22% increased risk of
ovarian cancer over 5 years was seen in postmenopausal women
using unopposed estrogen as HRT. The risk was still significantly
increased (by approximately 10%) by the application of a combi-
nation of estrogen and progestin (30, 31). Data from a study in
a large patient cohort in England revealed that the incidence of
ovarian cancer increased with longer duration of HRT therapy,
especially if HRT was taken for 10 or more years. There was a
higher relative risk for developing EOCs rather than MCs, ECs,
or CCCs. But the composition of the HRT did not influence the
risk (32). A more recent study revealed that women taking unop-
posed oral estrogen therapy have an increased risk of HGSCs,
LGSCs, and ECs. Only the risk for MCs was decreased. Similar, an
increased risk for serous carcinomas and ECs was found in women
receiving an estrogen/progestin combination as HRT (33). On the
other hand, women with previous HRT have a better prognosis
when diagnosed with ovarian cancer. They are more likely to be
diagnosed at younger age and lower tumor stage allowing a com-
plete surgical removal of the tumor mass (complete debulking
without any signs of a residual tumor mass). An increased over-
all survival, specifically in the subgroup of patients, which had
a complete debulking, was found in these studies. No correla-
tion was seen with the progression free survival (34). Data from
another study, however, showed that if HRT was administered
following tumor debulking, the prognosis remained unchanged.
Furthermore, the survival time was independent on the expres-
sion of estrogen and progesterone receptors (PGR) in the cancer
tissues. This study was done with a small number of patients
only, and therefore, data may not be representative for a larger
cohort of ovarian cancer patients (35). After tumor operation,
especially younger ovarian cancer patients may suffer from estro-
gen withdrawal symptoms, and therefore, they will consider HRT
treatment. Since data are not clear yet, studies with more patients
suffering from different types of ovarian cancer are urgently
needed.
OVARIAN CANCER HYPOTHESIS
To explain the effects of estrogens in the etiology of ovarian can-
cer, different hypothesis are available. The “incessant ovulation
hypothesis” was developed already in 1971, but the more recent
“incessant menstruation hypothesis” is now favored (36–38).
The incessant ovulation hypothesis
This hypothesis attributes ovarian cancer formation to repeti-
tive wounding during ovulation and the subsequent activation
of repair mechanisms. These processes are associated with an
increased number of mutations accumulating in epithelial cells.
This finally drives tumor formation and progression (39).
The association between sex steroids and cancer can be
explained by processes that take place during the menstrual cycles,
in which the ovarian surface epithelium (OSE) plays pivotal roles
during ovulation and postovulatory wound repair. Indeed, most
of the total proliferative activity of the OSE is related to ovula-
tion repair and formation of the corpus luteum. In the menstrual
cycle, the OSE covering growing follicles enters into the prolifera-
tive phase during pro-estrus/estrus transition. After the ovulation,
the proliferation rate of OSE cells covering the newly formed
corpus luteum decreases. Also, the exposure of the OSE to high
doses of the gonadotropins luteinizing hormone (LH) and follicle
stimulating hormone (FSH) during the menstrual cycle promotes
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cell proliferation and tumor growth (40). As a positive effect,
progesterone, which is increased during pregnancy and during
OCP application, promotes clearing of transformed cells from the
ovarian surface epithelial layers (37, 41).
The incessant menstruation hypothesis
High-grade serous ovarian cancer are sought to derive from cells
in the fimbriae of the fallopian tubes, which are floating in bloody
peritoneal fluid. Thereby, they are exposed to iron-induced oxida-
tive stress derived from retrograde menstruation. The genotoxic
effect of reactive oxygen species, generated from hemolysis of ery-
throcytes by pelvic macrophages would explain the distal site of
tubal intraepithelial neoplasia (37, 38, 41).
ESTROGENS AND OVARIAN CANCER
At the cellular level, tumor promoting effects of estrogen are
conferred in a (i) receptor-dependent and (ii) -independent way.
i) Receptor-dependent ways: binding of estrogen to the nuclear
estrogen receptor-α (ER-α) leads to the transcriptional acti-
vation of estrogen-responsive genes, which provide signaling
systems for cell division and differentiation. Among these genes
are proto-oncogenes, such as c-fos, c-myc, and HER2/neu; cell
cycle regulating cyclins, growth factors, and others (42). Bind-
ing to membrane-bound G-protein-coupled estrogen receptor
(GPER, formerly known as GPR30) activates second messenger
systems. Thereby, GPER confers rapid non-genomic effects of
estrogens (43).
ii) In a receptor independent way, formation of reactive metabo-
lites via cytochrome P450 enzymes (CYPs) may lead to the
generation of mutagenic DNA adducts. Free radicals generated
by the metabolic activation of estrogens cause mutations. Accu-
mulation of mutations in various genes in cells in the fallopian
tubes and in the ovary will lead to the neoplastic transformation
of cells (Figure 1) (10, 44, 45).
Description of pathways
i) Transcriptional effects of estrogens on target genes are mediated
by activation of nuclear receptors, the estrogen receptor-α (ER-
α), and estrogen receptor-β (ER-β). Upon binding of estrogens
to ER-α, transcription of a battery of genes, which stimulate cell
proliferation, is induced. Enhanced proliferation is associated
with an increased risk of mutations that accumulate in cells
finally leading to malignant transformation. ER-β was found
to counteract the growth stimulating effects of ER-α in ovarian
cancer cells (47).
Another member of the nuclear receptor superfamily, which
confers estrogenic effects in ovarian cancer is the estrogen-
related receptor-α (ERR-α). It is known to regulate metabolic
homeostasis under conditions of high energy demand, e.g., in
brown adipocytes. The increased expression and activity of
ERR-α was associated with a less favorable clinical outcome
of ovarian cancer (42).
Estrogens also promote tumor progression by influencing
signaling pathways. Via the seven-transmembrane spanning
G-protein-coupled receptor, named GPER, estrogen rapidly
Uterus
Ovary
Fallopian
Tubes
Transcrional acvaon
of nuclear receptors:
• Transcrip on of target
genes
Smulaon of GP-ER:
• Induc on of ERK, PI3K and
EGFR signaling
Estrogen Metabolism:
Forma on of
• Catechol metabolites
• Free radicals
• Mutagenic DNA adducts
Estrogen
a. Gene 
transcripon b. Second 
messengers
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Serous EOC 
FIGURE 1 | Pathways for estrogen to convert tumor promoting effects in
cells in the fallopian tubes and the ovaries. (a.) Activation of the nuclear
estrogen receptor-α (ER-α) leads to the transcriptional activation of
estrogen-responsive genes, which stimulate cell proliferation. (b.) Binding to
membrane-bound G-protein-coupled estrogen receptor (GPER) activates
second messenger systems. In cancer cells, estrogen induces
extracellular-signal regulated kinase (ERK), phosphoinositide 3-kinase (PI3K),
and epidermal growth factor receptor (EGFR) leading to enhanced cell
proliferation. (c.) The formation of reactive metabolites leads to the generation
of mutagenic DNA adducts. Free radicals from the metabolic activation of
estrogens will cause mutations. Accumulation of mutations will lead to
neoplastic transformation of proliferating cells (10, 42, 44–46)
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activates the extracellular signal-regulated kinases (ERK)-1 and
ERK-2, and confers estrogenic effects to cells devote of the clas-
sical nuclear ER (48). A recent study in endometrial cancer cells
showed that GPER mediates the estrogen stimulated induction
of the kinases ERK-1 and -2 and the phosphatidylinositol-4,
5-bisphosphate 3-kinase (PI3K) via activation of matrix metal-
loproteinase. This is followed by the subsequent transactivation
of the epidermal growth factor receptor (EGFR) (46).
ii) Metabolism of estrogen may cause DNA damage by the for-
mation of mutagenic purinergic DNA adducts and by genera-
tion of free radicals from the metabolic activation to reactive
catechol estrogens. Catechol estrogens are formed by aro-
matic hydroxylation of primary estrogens at either the C-2
or C-4 position. The catechol metabolites are inactivated by
their conjugation with active sulfate or uridine-diphosphate
(UDP)-glucuronic acid by steroid sulfotransferases (SULTs)
and UDP-glucuronosyltransferases, respectively. Before their
conjugation to more water-soluble metabolites, hydroxylation
of the steroid moiety via specific CYP isoenzymes, namely
CYP1A1 and CYP1A2, which catalyze hydroxylation in posi-
tion 2, and CYP1B1, which is an estrogen 4-hydroxylase, occurs
(44). Especially, 4-hydroxyestrogens can be oxidized to quinone
intermediates, which react with purine bases of the DNA. This
results in depurinating adducts, which generate highly muta-
genic, apurinic sites. 2-hydroxyestrogens produce less genotoxic
DNA adducts. Studies in rodents demonstrated that E2 and E1,
as well as their catechol metabolites, in particular 4-hydroxy
E2/E1 (4-OH E2/E1), have carcinogenic effects. In a redox cycle,
4-OH E2/E1 is converted to the quinone derivatives. The con-
version back to 4-OH E2/E1 is associated with the formation
of oxygen radicals. DNA mutations caused by free radicals will
lead to the neoplastic transformation of cells (45).
ESTROGEN AND BRCA1/2 MUTATIONS
Breast and ovarian cancer mostly arise sporadically, but a small
number of cases (approximately 10%) of these cancers are asso-
ciated with mutations in BRCA1/2 genes. Defects in the DNA
damage response or in the DNA repair pathways in patients with
the BRCA1/2 mutation are responsible for the high penetrance
of these cancers in the breast and/or ovary. It was shown that
carriers of BRCA1/2 mutations have also increased levels of estro-
gen, which may trigger breast and ovarian cancers (49). Indeed,
in premenopausal patients with BRCA1/2 mutations, removal of
both ovaries and of the fallopian tubes reduces the risk of these
cancers (50).
ESTROGEN SYNTHESIS IN OVARIAN CANCER CELLS
During the reproductive years, ovaries produce and release prog-
esterone and the estrogens estrone (E1), 17β-estradiol (E2), and
estriol (E3).
E2, the most active form of natural estrogens, together with
progesterone is critical for normal uterine function, establishment
and maintenance of pregnancy, and mammary gland develop-
ment. Furthermore, it is responsible for endocrine, paracrine, and
autocrine actions in various tissues and organs. Ovarian steroid
hormone formation takes place in the ovarian granulosa and
theca cells, which work in a collaborative way for the synthesis
after stimulation by the gonadotropins LH and FSH. Theca cells
respond to LH signaling by increasing the expression of steroid
synthesizing enzymes for the transformation of cholesterol to
the androgens (5-androstenedione and testosterone). Granulosa
cells respond to FSH signaling by stimulating the expression of
enzymes for the synthesis of estrogens (E2 and E1) from androgen
precursors (51).
While in premenopausal women, the main part of active estro-
gens derives from the synthesis in the ovary, after the menopause,
estrogens are formed locally in various tissues such as in liver,
brain, and adipose tissue. There, E2 is produced from circulating
androgen and estrogen precursors. These precursors are bound
to sex-steroid binding globulins in the blood. They are trans-
ported to the ovary, where they are taken up into ovarian epithelial
cells by transporters, e.g., from the family of organic anion trans-
porting peptides (OATPs) (52). The importance of the visceral
adipose tissue of postmenopausal women for E2 production is
reflected by the high concentrations of estrone-sulfate (E1-S), 5-
androstendione, and dehydroepiandrosterone-sulfate (DHEA-S)
in these cells. The local concentrations are up to 60×higher than in
serum, while E2 and testosterone levels are increased by sevenfold
only (53, 54).
The biological activity of estrogen is regulated independent on
the expression and activity of receptors by the expression and func-
tion of steroid (estrogen)-metabolizing enzymes expressed locally
at the target tissues. Among these enzymes, aromatase (CYP19A1),
steroid sulfatase (STS), and 17β-hydroxysteroid dehydrogenases
(17β-HSD) are highly important.
In hormone-dependent cancer, formation of the biological
most active estrogen E2 from steroid precursors is mediated via
the aromatase and the sulfatase pathway (Figure 2).
In the aromatase pathway, steroid precursors derived from the
circulation, like dehydroepiandrosterone (DHEA), are first con-
verted to testosterone and, subsequently, by the aromatase, E2 is
generated.
In the sulfatase pathway, the sulfate moiety is removed by
STS from the inactive E1-S to form the active estrogen E1. E1
is converted to E2 by the reducing 17β-HSD isoenzymes. In the
inactivating pathway, E2 is oxidized to E1 by 17β-HSD enzymes.
E1, which exerts also estrogenic effects via binding to ERs, can be
inactivated by estrogen sulfotransferase (SULT1E1). The resulting
inactive E1-S can again become activated by the removal of sulfate
(7, 55).
The precursor of all steroid hormones is cholesterol, which
is mainly derived from the synthesis, particularly in the liver,
or from the nutrition. Cholesterol is converted over a few steps
to pregnenolone, and next to progesterone. Progesterone acts as
the starting point for all steroid hormones in the adrenal cortex
and in various other peripheral organs, e.g., the liver. The steroid
hormone precursors DHEA, its sulfate metabolite DHEA-S, 5α-
androstenediol sulfate (5-Diol-S), and E1-S are also synthesized in
large quantity there. They are released into the circulation.
In the group of postmenopausal women, the levels of E2 and
progesterone are up to 90% lower than those from premenopausal
women. However, the concentration of other steroid hormones
(DHEA, 5-Diol-S) is similar in pre- and postmenopausal women.
After the menopause, E1-S is the most abundant estrogen in the
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FIGURE 2 | Pathway for 17β-estradiol formation in cancer cells.
Estrone-sulfate (E1-S), a precursor for the most active estrogen
17β-estradiol (E2), androstenediol (5-Diol-S), and dehydroepiandrosterone
sulfate (DHEA-S) are taken up from the blood into cancer cells by
transporters from the organic anion transporting polypeptide family
(OATPs) and other members of the solute carriers (SLCs). In the sulfatase
pathway, E1-S is converted through steroid sulfatase (STS) to estrone (E1),
which is transformed via the reductive 17β-hydroxysteroid dehydrogenases
(17β-HSD red) to E2. E2 as the most active estrogen binds and activates
estrogen receptors (ERs). In the reverse pathway from E2 to E1-S, the
oxidative 17β-hydroxysteroid dehydrogenases (17β-HSDox) convert E2 to
E1. The estrogen sulfotransferase SULT1E1 inactivates estrogens by
adding sulfate to hydroxyl-groups on the steroid ring. In the aromatase
pathway, E2 is produced from testosterone by the aromatase.
Testosterone itself is formed from 5-androstenediol (5-Diol) via 3β-HSD.
5-Diol is generated by the removal of the sulfate from 5-Diol-S via STS.
Also 5-Diol can activate ER, but with lower affinity than E2. In an
alternative way, testosterone is derived from the conversion of DHEA-S to
androstenedione (4-Dione) via DHEA. Finally, 17β-HSD transforms 4-Dione
to testosterone (55).
peripheral blood of women. Ten to thirty percent of estrogens in
serum are bound to sex-steroid binding globulins in order to pro-
vide a reservoir for peripheral formation of E2. These proteins
are synthesized in the liver after the stimulation with estrogen and
thyroid hormones. Progesterone inhibits their production (56,57).
ESTROGEN SYNTHESIS IN HORMONE-DEPENDENT CANCERS
Epidemiological and experimental studies showed that higher
endogenous estrogen exposure through early menarche (<12 years),
late menopause (>55 years),nulliparity,obesity (postmenopausal),
use of postmenopausal HRT, and increased plasma E2 levels lead
to an increased risk of breast cancer. Of particular importance
is the circulating inactive plasma estrogen precursor E1-S, which
has been reported to serve as the predominant source for tumor
E2 in postmenopausal patients with breast cancer. E1-S is derived
from peripheral tissues, including the adrenal gland, adipocytes,
liver, muscle, skin, and bone (54). Following its cellular uptake
by transporters of the OATPs family (52), E1-S is desulfonated
to E1 by STS and E1 is further converted to E2 by 17β-HSDs.
This intracellular production of E2 stimulates the proliferation of
estrogen-dependent tumor cells (58). As compared to the other
sources of unconjugated estrogens (which act as precursors for
the aromatase pathway), E1-S (precursor for the sulfatase path-
way) has about 5–10 times higher plasma circulating levels than
other estrogens (59). Moreover, sulfatase activity is 130–200 times
higher than aromatase activity (60) and the concentration of sul-
fatase is three times higher in breast cancer tissues than normal
tissues (61). Two-thirds of all breast cancers have a positive ER
status and as consequence, they are sensitive to estrogens. These
tumors respond well to hormone therapy (62). Also in endome-
trial cancer, biosynthesis of active estrogen is achieved from E1-S,
which is transported into endometrial cells, where it is converted
to E2 by STS and 17β-HSDs (63).
ENZYMES IN THE ESTROGEN METABOLISM PATHWAY
STEROID SULFATASE
Steroid sulfatase is a member of the arylsulfatase family, which
is known for the hydrolysis of sulfate ester bonds in a wide
Frontiers in Endocrinology | Experimental Endocrinology November 2014 | Volume 5 | Article 192 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mungenast and Thalhammer Estrogen metabolism in ovarian cancer
range of substrates. The corresponding gene is located on the
X-chromosome and contains 10 exons. The group of Hernandez-
Guzman et al. (64) was the first to isolate STS from the human
placenta, to purify and crystallize it. This enzyme consists of two
membrane-spanning hydrophobic alpha helices that are arranged
anti-parallel. The amino acid proline on position 212 acts on the
cytosolic side of the endoplasmatic reticulum membrane as turn-
ing point. STS is present in the ER of many tissues and is especially
high in ovarian granulose cells (65, 66). It plays an essential role in
the synthesis of E2, by converting E1-S into active E1 (Figure 2).
ESTROGEN SULFOTRANSFERASE
Estrogen sulfotransferase belongs to the family of SULTs, phase
II detoxification enzymes. Ten isoforms of SULT are known to
be expressed in humans. These enzymes have a wide range of
substrates including hydroxysteroids, thyroid hormones, phenols,
arylamines, and primary alcohols. Because SULT1E1 has the high-
est affinity of all SULTs for E1 and E2, it is also called estrogen
specific sulfotransferase. It catalyzes the transfer of a sulfuryl group
from 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to nucle-
ophilic groups of SULT1E1 substrates. PAPS are synthesized by
PAPS synthesizing enzymes (PAPS synthetases).
Estrogen sulfotransferase acts in an antagonistic way to STS by
converting E1 to E1-S. Therefore, it is inactivating the estrogen.
The corresponding gene is located on chromosome 4q3.12, has
eight exons and a length of 20 kB. SULT1E1 is present in vari-
ous tissues, including liver, testis, mammary epithelium cells, and
endometrium (67–69).
17β-HYDROXYSTEROID DEHYDROGENASES
17β-HSDs form a family of enzymes (14 isoforms in vertebrates)
that catalyze the conversion between highly active 17β-hydroxy
steroid hormones and 17-keto steroid hormones with lower or
even missing activity. 17β-HSD isoenzymes have different enzy-
matic properties and a characteristic cell-specific expression pat-
tern according to their different physiological functions. They are
multifunctional and modulate other steroid structures as well.
Among their substrates are bile acids, retinoids, fatty acids, and
others.
The reductive 17β2-HSD isoenzyme activates E1 to E2 and
4-Dione to testosterone. Also the isoforms 7 and 12 are reduc-
tive estrogenic enzymes. In contrast, isoforms 4, 8, 10, and 14 are
oxidative enzymes responsible for E2 inactivation (63).
In the normal ovary, 17β-HSDs are detected in granulosa cells
of developing follicles, but not in the normal OSE. However, a
variety of EOC have been reported to be positive for different
17β-HSD isoenzymes.
For example, a recent study showed that reducing 17β12-HSD
is overexpressed in many human carcinomas including ovarian
carcinoma, while it is not present in the normal OSE. Importantly,
patients with EOC tumors with a weak or moderate expression of
17β12-HSD had a better overall survival than those with strongly
17β12-HSD positive tumors (55).
ESTROGEN RECEPTORS
ESTROGEN RECEPTORS-α/-β
Currently, two isoforms of the nuclear ER, namely ER-α and ER-
β are known. In 1996, Kuiper et al. (70) cloned the second ER,
named ER-β from rat testis. As a consequence, ER was renamed
to ER-α. The two ERs are encoded by the ESR1 and ESR2 genes.
Alternative promoter usage and splicing produces various tran-
script variants. However, expression pattern and function of many
of these variants has not been determined so far.
The ERs are members of the nuclear receptor superfamily of
steroid receptors and function as ligand inducible transcription
factors (71). The nuclear receptor superfamily structure is defined
through five different domains, namely A/B, C, D, E, and F. Each
domain fulfills another obligation, which is essential for the correct
function of the receptor. The A/B domain, also named N-terminal
domain includes a ligand independent activation function (AF-1).
This domain also has a rather poor (20%) homology with the other
ER isoform (72). This gives a hint that this region takes mainly part
to the ER subtype specific actions on target genes. Moreover ER-α
seems to have a stronger corresponding AF-1 function than ER-
β (73). The DNA-binding domain C is responsible for specific
DNA-binding and receptor dimerization. This highly conserved
domain shows a high homology between ER-α and ER-β. The D-
domain is a flexible hinge with the ligand-binding domain and
is called “Hinge domain.” ER-α shares only 30% homology in
this domain with ER-β. It contains a nuclear localization signal,
which is essential for the transport of ERs to the nucleus. The
ligand-binding E-domain is responsible for hormone-dependent
activation (AF-2), ligand binding, and together with the DNA-
binding domain for receptor dimerization. ER-α and ER-β show
a homology of 55% in the ligand-binding domain (74, 75). The
amino acid sequence of the ligand-binding cavity varies only in
two positions, but this leads to a significant smaller cavity in
ER-β. This may be an advantage for receptor subtype specific
drugs (76, 77). The function of the F domain is still not clear.
A dimerization of ER is necessary for transcriptional activation.
Either a homodimer of one ER isoform or a heterodimer of ER-
α and ER-β is active (73). The regulation of the transcription of
target genes is achieved by binding of the receptors to estrogen
response elements in target genes. This is followed by recruitment
of a variety of coregulators to alter chromatin structure and facil-
itate the recruitment of the RNA polymerase II transcriptional
machinery (78).
Estrogen receptors mediate many estrogenic effects on gene
regulation and, therefore, ERs are essential for various develop-
mental and functional processes in several tissues/cells (79). ERs
are important for sexual development and reproductive function,
but also play a role in other tissues such as bone.
ER-α is the predominant ER in the uterus, mammary gland,
testis, pituitary, liver, kidney, heart, and skeletal muscle (80–82).
Some ER-α target genes mediate proliferation and cell survival
(83). Importantly, sustained estrogenic exposure and activation
of ER-α may increase the risk and/or the progression of various
cancers, including cancers in the breast and endometrium.
The ER-β gene consists of eight exons and through alternative
splicing five isoform, namely ER-β1-5 are generated by dele-
tion of one or more exons. Human ER-β1 protein has a length
of 530 amino acids (84, 85). ER-β is predominantly expressed
in ovary and prostate (80–82). In contrast to ER-α, ER-β acti-
vates antiproliferative and pro-apoptotic pathways in many cancer
cells (83).
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THE MEMBRANE-BOUND G-PROTEIN-COUPLED ESTROGEN RECEPTOR
G-protein-coupled estrogen receptor functions as a G coupled
plasma membrane-associated receptor and works independent of
nuclear ERs. It binds various estrogens including E2, E1 and E3, ER
antagonists, phytoestrogens, and xenoestrogens (86). GPER, which
mediates rapid estrogen signaling via stimulation of adenylyl
cyclase, is expressed in normal ovary, where it regulates physiolog-
ical processes such as follicle maturation. The receptor is expressed
in many EOC samples. However, the prognostic impact of GPER
expression in EOC is controversial. In an earlier study, GPER was
seen to be preferentially expressed in “high risk” tumors with a
worse prognosis (87). Later, no relation between GPER expres-
sion and survival rates of EOC patients was found (88). Recently,
GPER expression was shown to correlate with gonadotropin
(LH and FSH) receptors. Only in EOCs, which are negative for
gonadotropin receptors, a higher GPER expression was associated
with a more favorable outcome for the patients. These findings
suggest that GPER may reduce ovarian cancer cell proliferation in
the absence of gonadotropin signaling only (89). Therefore, syn-
thetic agonists and antagonists for GPER, which are now available,
might be tested in gonadotropin receptor-negative tumors of EOC
patients (90).
PROGESTERONE AND PROGESTERONE RECEPTORS
Progesterone is synthesized from cholesterol in the corpus luteum,
follicles, placenta, and in other organs, e.g., the adrenal gland.
During transport through the blood plasma, it is bound to corti-
sol binding globulin, because of its lipophilic nature and also to
avoid degradation.
In the ovary, progesterone plays an important role in the fol-
licle maturation and moreover, it is responsible for preparing the
female genital tract for pregnancy. It also maintains the pregnancy
after fertilization. Progesterone promotes the growth of the uterus
musculature and changes the endometrium from a proliferative to
a secretory tissue. It also decreases the myometrium activity dur-
ing pregnancy and changes the quality and quantity of the cervix
mucus, thus preventing the entrance of sperms into the uteri and
the tubes. In the ovary, it works in concert with estrogen to pro-
mote follicle maturation, ovulation, and formation of the corpus
luteum.
The effects of progesterone are mediated by the two mem-
bers of nuclear PGR isoforms. Like other receptors of this family,
PGR consists of four domains, namely the ligand-binding domain,
the Hinge-Region as the flexible link between the ligand-binding
domain and the DNA-binding domain, and the N-terminal
domain (91). The two isoforms PR-A and PR-B are encoded by one
gene but the transcription is carried out by two different promot-
ers. Apart from the lack of a 164 amino-sequence at the N-terminal
end in PR-A, the two PGRs are identical. PR-B is responsible for the
transcriptional activation of progesterone responsive genes, but it
can be inhibited by PR-A (92–95). PR-A and PR-B act either as
homo- or heterodimers and both are synthesized in equal amounts
in normal epithelial cells (96).
Progesterone as an antagonist of estrogen has an antiprolif-
erative effect on specific cells. It acts in part by decreasing the
production of ERs, and through activation of 17β-HSD and
SULT1E1. Indeed, elevated PGR levels were associated with a
significantly better survival rate in EOC patients as data from a
recent meta-analysis showed (97).
ESTROGEN SYNTHESIZING ENZYMES AND RECEPTORS IN
OVARIAN CANCER
There is evidence that estrogens play a role in the progression of
ovarian cancer. An overexpression of STS will lead to an increased
level of E2 and this may contribute to cancer progression. In post-
menopausal women, the local conversion from circulating steroid
hormone precursors, e.g., E1-S and DHEA-S to active E2 could
promote ovarian cancer progression.
Indeed, the expression levels of key enzymes vary between nor-
mal tissues and different subtypes of EOC. For example, STS was
detected in 30% of serous carcinomas, in 70% of CCCs, and in
8% of MCs (98). Ovarian cancer studies further showed that a
longer progression free survival is significantly associated with
lower STS levels. That can be explained by the fact that through a
high expression of STS, more E2 is synthesized (99). Similar effects
of STS were also reported from breast cancer studies, where STS
activity correlated with the E2 serum levels. On the opposite, high
estrogen inactivating SULT1E1 levels were associated with smaller
tumors, a better prognosis, and a negative lymph node status in
ovarian cancer patients (100–103). In the same way, in breast can-
cer a high expression of SULT1E1 together with a decreased level
of STS correlates with a better prognosis, smaller tumor size, and
a negative lymph status at the time of diagnosis. Another evi-
dence that SULT1E1 acts as a tumor suppressor is based on a study
with xenograft models carried out by Xu et al. (69) showing that
an overexpression of SULT1E1 inhibited estrogen-dependent cell
growth and induced tumor cell apoptosis.
High E2 levels were often observed in ovarian cancer patients
(102). E2 was shown to increase the mobility of ovarian cancer
cells via the inhibition of cell–cell adhesion. This promotes metas-
tasis (104), and a similar effect of E2 was also observed in breast
cancer (105).
Mostly earlier studies in ovarian cancer patients reported that
high levels of ER-α and low levels ER-β are associated with a worse
prognosis (106–110). However, in other studies, high expression of
ER-αwas found to be associated with a better prognosis (111, 112).
Also higher ER-β levels were significantly associated with longer
disease-free survival and a longer overall survival in one study.
The reduction of ER-β significantly correlated with the hyper-
methylation of the ER-β promoter, causing an inhibition of gene
translation (113). A proof for the protective effect of ER-β is that
this isoform is the dominant ER isoform in healthy ovaries. But in
all serous tumors and also in metastasis, ER-α is usually dominant,
and ER-β expression is rather weak. This leads to the conclusion
that the gradual reduction of ER-β during tumor progression
(from normal to borderline to malign tissue to metastasis) is a
continuous process and important for malignant transformation
and cancer cell proliferation (114, 115).
Progesterone has been proved to decrease the proliferative effect
of estrogens and inhibit inflammation and cancer penetration by
suppressing ovulation. It also initiates apoptosis in tumor cells.
PGR is a biomarker for a better prognosis and longer overall sur-
vival in ovarian cancer (116). This is in line with findings that PGR
levels are significantly lower in benign, borderline, and malignant
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ovarian tumors than in healthy tissue (108, 117). Recently, a multi-
center investigation in 2933 women with invasive EOCs showed
that PGR and ER are positive prognostic biomarkers for ECs and
HGSCs (118).
OVARIAN CANCER AND HORMONAL TREATMENT
There is evidence that estrogen has an influence on the progres-
sion of the EOCs at least in some subgroups of patients (119).
To combat estrogen stimulated tumor cell growth, selective estro-
gen receptor modulators (SERMs) that function as agonists or
antagonists for ERs, have been developed. However, modulation
of the tissue-specific expression of ER subtypes, expression of
co-regulatory proteins, and varying ER conformational changes
induced by ligand binding may change the activity of the hor-
monal therapy. The best studied SERM is tamoxifen that is highly
effective to block the ER-signaling pathways. It prevents breast
cancer recurrence in many patients with positive ER status. In
postmenopausal patients failing tamoxifen therapy, the synthesis
of estrogen can be blocked by aromatase inhibitors anastrozole,
letrozole, and exemestane (120).
In ovarian cancer, the therapeutic value for SERMs and aro-
matase inhibitors to block tumor progression and recurrence is
not thoroughly established, yet. Only small-scale studies were
done so far. Additionally, in the few studies, the patients were
not selected based on their hormone-receptor status (ER positive
or negative) or age (pre- vs. postmenopausal). Moreover, in some
studies, patients were only selected after resistance to standard
chemotherapy. Later, the group of Tropé et al. (121) compared
data from different studies with tamoxifen (in total a collective of
647 patients) and found a response rate ranging from 0 to 56%,
with a mean response rate of 11%. The treatment with aromatase
inhibitor letrozole showed a response rate ranging from 0 to 35.7%,
with stable disease rates ranging from 20 to 42% (122–124). For
anastrozole, response rates of 1.9–4.3% and stable disease rates of
42–61% were reported (125, 126).
Whether ovarian cancer patients, who express ERs and estrogen
synthesizing enzymes such as STS and 17β-HSDs in their tumors,
may have a better response rate to hormonal therapy, should be
investigated. Nevertheless, inhibition of estrogen activating STS
would offer a novel approach to combat ovarian cancer. Among
already available STS inhibitors, the cyclopentane carboxylate
derivate STX64 (irosustat) is currently undergoing clinical trials
for therapy of prostate, endometrial and breast cancer. With this
drug, serum levels of E1, E2, 4-Dione and DHEA were decreased
and stable disease for up to 7 months was even seen in breast
cancer patients with advanced disease. However, for a more effi-
cient depletion of tumor estrogen, application of STS inhibitors
together with an aromatase inhibitor could also be of benefit in
postmenopausal women in order to block both, E2 formation via
the aromatase and sulfatase pathway (57). Also, subgroups of ovar-
ian cancers should be studied in different therapeutic settings. This
would help to identify patients, for which hormonal therapy might
offer an additional possibility to prevent recurrence of ovarian
cancer.
SUMMARY
Ovarian cancer is the deadliest of all gynecological malignancies
in women and these tumors are usually seen in women after the
age of 50 years. The still poor prognosis for ovarian cancer is partly
attributed to the fact that the diagnosis is usually made at a late
stage,when the cancer has already spread to other organs. There are
only limited options for a successful chemotherapeutic treatment
so far and novel strategies are needed.
Several epidemiological and experimental data revealed that
ovarian cancer shares many estrogen regulated pathways with
other hormone-dependent cancers, e.g., breast cancer. Therefore,
local estrogen synthesis from circulating steroid hormone precur-
sors by steroid-forming and steroid-inactivating enzymes may be
important to drive ovarian cancer progression in women after
the menopause. Indeed, these enzymes and receptors were iden-
tified in ovarian cancer cells and their expression was shown to
be related to clinical parameters. So far, such studies were mostly
done in a small group of patients, which were not selected based
on their age, ovarian cancer subtype, hormone-receptor status,
and resistance to standard chemotherapy. Because ovarian cancer
is a heterogeneous disease and tumors vary with respect to their
origin, behavior, and prognosis, they may also differ in their sensi-
tivity to hormonal therapy. At least in subgroups of patients, who
express enzymes for estrogen biosynthesis and receptors for estro-
gen signaling in their tumors, hormonal therapy might offer an
additional possibility to prevent recurrence of ovarian cancer.
The review explains the role of estrogen in ovarian cancer and
it gives an overview on ovarian cancer subtypes. Furthermore,
enzymes active to synthesize and metabolize estrogens as well as
estrogen signaling pathways are described. Strategies to target these
pathways are discussed.
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